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letter to editorMiR-125b and
miR-99a encoded on
chromosome 21
co-regulate vincristine
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To the Editor: MicroRNAs (miR-
NAs) are small, non-coding RNA
of 20–22 nucleotides in length
which can silence speciﬁc target
genes through direct mRNA deg-
radation, translational repression,
or both. miRNAs are involved in
several cellular processes like cell
cycle, apoptosis, drug resistance
and differentiation.1 In 2011,
Schotte et al. reported different
miRNA signatures in pediatric
acute lymphoblastic leukemia
(ALL) with various genetic sub-
types and drug-resistance. miR-
125b, miR-99a, and miR-100 were
upregulated20-fold in vincristine
and daunorubicin-resistant ALL
cells.2 Recent reports suggested
that co-expression of miR-125b in
combination with miR-100, or
miR-99a, or miR-100 and miR-
99a induces signiﬁcant vincristine
(VCR) resistance in ETV6-
RUNX1-positive Reh leukemic
cells. The authors noted that the
miR-125b isoforms, (miR-125b-1
and miR-125b-2), were located
downstream to miR-100 and
miR-99a, respectively. Also, both
miR-100 and miR-99a differed by
a single nucleotide. Therefore, co-
expression of miR-125b/miR-99a,
miR-125b/miR-100 or miR-125b/
miR-99a/miR-100 is required for
VCR resistance.3
A growing body of evidence
suggests the crucial role of miR-
NAs in the regulation of differen-
tiation in normal as well as
malignant hematopoiesis.4 Screen-
ing of miRNA for this drugHematol Oncol Stem Cell Ther 8(2) Second Quarter 2resistance is needed to estimate
the prognosis of the disease and
to identify better drug targets. Five
miRNAs (miR-99a, let-7c, miR-
125b-2, miR-155 and miR-802)
are encoded on chromosome 21,
and are potential players in the
pathogenesis of transient myelo-
proliferative disorder (TMD).
TMD of Down syndrome is a
hematologic abnormality which is
characterized by an uncontrolled
proliferation of myeloblasts in
bone marrow and peripheral blood
that affects babies with trisomy of
chromosome 21.5 Interestingly,
four of the ﬁve miRNAs encoded
in chromosome 21 (miR-99a, let-
7c, miR-125b-2, and miR-155)
play a crucial role in megakaryo-
cyte development.
Our laboratory is studying the
miRNA expression level of miR-
125b and miR-99a in VCR resis-
tant and developmentally different
CMK (child) and MEG-01(adult)
megakaryoblastic leukemia cell
lines. MEG-01 cell line was estab-
lished from the bone marrow of a
patient with blast crisis of Philadel-
phia chromosome-positive chronic
myelogenous leukemia, and VCR
showed no activity against these cells.
To show variation in VCR resis-
tance, the cell lines were grown in
RPMI 1640 (GIBCO BRL, Grand
Island, NY, USA), media supple-
mented with 10% fetal bovine
serum and 1% antibiotics. miRNA
(n = 3) was prepared using the
miRNeasy mini kit (Qiagen),
expression analysis of miR-99a
was determined using qRT-PCR,
and the data was analyzed by Ct
method. Putative targets of miR-
125b and miR-99a were explored
using bioinformatic tools such as
TargetScan, PicTar, RNAhybrid,
and miRBase. A conﬁrmatory wes-
tern blot analysis of the targets was
performed by standard method.015First, we compared miR-99a
levels in CMK and MEG01 by
quantitative PCR and found
8.5-fold upregulation in CMK
compared to MEG01 (p < 0.01,
n = 3) (Fig. 1A). Our previous
report had shown overexpression
of miR-125b by nearly 7.5-fold
(p < 0.05, n = 3) in CMK cells
compared to MEG-01 cells. We
found that miR-125b downregu-
lates p53, BAK1 and CDK6
expression.6 High expression of
miR-125b has previously been
correlated with drug resistance in
leukemia.3 Previous studies and
the current literature show that
miR-99a and miR-100 are overex-
pressed in childhood acute myeloid
leukemia (AML).9,10 In contrast,
miR-99a and miR-100 were
downregulated in childhood ALL
patients, and their expression lev-
els were related to the prognosis
of ALL patients. But the current
study is the ﬁrst report of involve-
ment of miR-125b and miR-99a in
VCR resistance of the mega-
karyoblastic leukemia cell line,
CMK.
The clariﬁcation of miRNA
targets remains a major issue in
the functional examination of
miRNAs. Putative targets of
miR-99a using bioinformatics
tools were found to be FKBP51
and IGF1R (Fig. 2). A recent
study shows that deregulation of
microRNA-100/99a suppresses
proliferation and promotes apop-
tosis by regulating the FKBP51
and IGF1R/mTOR signaling
pathways in ALL. The study pro-
vided evidence that microRNAs
such as miR-99a and miR-100
act as tumor suppressors in ALL
cell lines.8
Based on these results, we per-
formed protein expression studies
of FKBP5 along with IGF1R in
CMK and MEG01 cells. We95
MEG01 CMK
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Fig. 1. Expression of miR-99a and its targets in CMK vs MEG01 cells. (A) miR-99a levels in CMK relative to MEG01 cells by real-time PCR. Bars
represent means € SD of three independent experiments (n = 3,*p < 0.01). (B) Increased miR-99a activity results in decreased protein expression of
FKBP51, IGF1R and increased p-Akt Ser473 in CMK cells by western blot analysis (n = 3).
Fig. 2. Minimum free energy (MFE) duplexes of the miR-99a and FKBP5 as well as IGF1R 30UTR analyzed by RNAhybrid.
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letter to editorfound a 0.5-fold downregulation
in CMK compared to MEG01
(p < 0.01, n = 3) of FKBP5 and
IGF1R protein levels by western
blot analysis (Fig. 1B). Increased
miR-99a activity resulted in
decreased expression of FKBP51
and IGF1R by binding to their
mRNA, leading to translational
arrest and causing increased
p-AKT Ser473 in CMK cells
(Figs. 1B and 2). Recently,
immunophilin FKBP51 (also
known as FKBP5) was identiﬁed
as a scaffolding protein that can
enhance PHLPP-AKT interaction
and facilitate PHLPP-mediated
dephosphorylation of AKT-
Ser473.11 Downregulation of
FKBP51 results in decreasedPHLPP-AKT interaction and
increased AKT phosphorylation.7
Our ﬁndings in VCR-resistant
acute megakaryoblastic leukemia
cell line (CMK) derived from
Down syndrome patients have
shown an overexpression of miR-
99a regulating its targets FKBP5
and IGF1R.
The present study suggests that
the co-expression of miR-125b
and miR-99a contributed to the
VCR resistance to CMK cells
due to actively transcribed
miR99a/miR-125b locus on chro-
mosome 21q21.1. Since miR-99a
and miR-125b are located on chro-
mosome 21, an additional copy in
Down syndrome correlates to the
overexpression of these miRNAsHematoand co-expression of these leads
to VCR resistance. Further studies
to establish the role of these miR-
NAs as a therapeutic strategy in
leukemia need to be explored.CONFLICT OF INTEREST
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